Philip J. Mease, MD, highlights the potential of blood biomarkers to assist with diagnosing fibromyalgia, as well as other imaging modalities.
This is a video synopsis/summary of a panel discussion involving Philip J. Mease, MD.
Despite progress in approved medications for fibromyalgia, there are significant unmet needs, such as lack of awareness among patients and clinicians. Education dissemination is crucial to bridge this gap. Additionally, the field anticipates advancements in new therapies, driven by ongoing pain research to unravel pain mechanisms and identify treatment targets. Philip J. Mease, MD, expresses hope for a future with additional treatments beyond the current pharmacological options. Advancements in diagnostic biomarkers, including blood biomarkers to distinguish fibromyalgia from autoimmune diseases, and improvements in neuroimaging for better identification of affected individuals, are also anticipated. These developments hold promise for enhancing understanding and addressing the complexities of fibromyalgia. The speaker emphasizes the importance of these future prospects in advancing fibromyalgia care.
Video synopsis is AI-generated and reviewed by HCPLive editorial staff.